Publications by authors named "David Catlin"

3 Publications

  • Page 1 of 1

Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.

Am J Addict 2021 01 16;30(1):43-48. Epub 2020 Jul 16.

Department of Psychiatry, University of Wisconsin, Madison, Wisconsin.

Background And Objectives: The factors associated with medication for opioid use disorder (MOUD) treatment retention among pregnant women with opioid use disorder (OUD) are largely unknown. This study sought to characterize factors associated with postpartum treatment retention.

Methods: A retrospective chart review from 2014 to 2017 was conducted among women with OUD in pregnancy treated with buprenorphine. Women were assigned to the treatment retention group if they attended an appointment within 10 to 14 weeks postpartum. Others were assigned to the dropout group. The groups were compared using bivariate analysis for sociodemographic variables, obstetrical and neonatal outcomes, clinical and subjective opioid withdrawal symptoms, buprenorphine dosage, urine drug toxicology (UDT) results, and other factors.

Results: A total of 64 pregnancies received treatment until delivery, and 47 (73.1%) were retained in treatment by 12 weeks postpartum. The treatment dropout group had lower buprenorphine doses at delivery, a higher percentage of benzodiazepine positive UDT, and number of UDT positive for benzodiazepine in the third trimester. Breastfeeding rates were higher in the treatment retention group.

Discussion And Conclusions: Future research of variables related to postpartum treatment retention is needed to provide guidelines regarding MOUD during the perinatal period and to optimize maternal and fetal well-being.

Scientific Significance: This study supports previous recommendations that aggressive treatment of withdrawal symptoms in pregnant women with OUD is needed to maximize treatment retention. This is the first study to find that breastfeeding was associated with postpartum treatment retention; while, increased use of benzodiazepines during pregnancy was associated with postpartum treatment dropout. (Am J Addict 2021;30:43-48).
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajad.13084DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772251PMC
January 2021

Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence.

Drug Alcohol Depend 2018 11 15;192:146-149. Epub 2018 Sep 15.

Department of Psychiatry, University of Wisconsin, 6001 Research Park Blvd, Madison, WI, 53719 USA. Electronic address:

Background: The treatment of pregnant women with opioid use disorder is challenging due to the myriad of physical, mental, and social complications. Factors influencing adherence to buprenorphine during pregnancy have not been identified.

Materials And Methods: Pregnant women with opioid use disorder followed in a tertiary clinic were included in a retrospective chart review from buprenorphine induction through delivery. All women who had been evaluated and treated with buprenorphine from January 1, 2014, to September 31, 2016, were included. Adherence was defined as follows: 1) adherent: attended follow up visits, negative urine toxicology screens, and phase advancement; 2) moderately adherent: attended follow up visits until delivery, had not completed six negative urine toxicology screens, or had positive urine toxicology screens (i.e., no phase advancement); 3) non-adherent: missed follow up visits and did not stay in treatment until delivery. Sociodemographic characteristics, family psychiatric history, current and lifetime psychiatric and childhood trauma along with treatment factors were compared by category of adherence.

Results: 64 women met criteria for inclusion in this study with 41 (64%) adherent; eight (13%) moderately adherent; and 15 (23%) non-adherent. In the non-adherent group compared to the adherent group, the clinician-rated opioid withdrawal scale score was significantly higher, and the daily buprenorphine dose at last visit was significantly lower.

Conclusions: Women who were non-adherent to buprenorphine during pregnancy had higher severity of opioid withdrawal symptoms and lower doses of buprenorphine. These findings should be further explored with the goal of optimizing care without increasing risk for neonates.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2018.07.042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741779PMC
November 2018

High-resolution imaging of the human retina with a Fourier deconvolution technique.

J Opt Soc Am A Opt Image Sci Vis 2002 Aug;19(8):1515-23

The Blackett Laboratory, Imperial College of Science, Technology and Medicine, London, UK.

A high-resolution retinal imaging camera is described that uses a Shack-Hartmann wave-front sensor and a Fourier deconvolution imaging technique. The operation of the camera is discussed in detail and high-resolution retinal images of the human cone mosaic are shown for a retinal patch approximately 10 arc min in diameter from two different retinal locations. The center-to-center cone spacing is shown to be approximately 2.5 microm for the retinal images recorded at 2 degrees temporal from the central fovea and approximately 4 microm for the retinal images recorded at 3 degrees temporal from the central fovea.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1364/josaa.19.001515DOI Listing
August 2002
-->